OR4F4: A Potential Drug Target and Biomarker for Ovarian Cancer
OR4F4: A Potential Drug Target and Biomarker for Ovarian Cancer
Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,120 new cases and 6,930 deaths in the United States alone in 2020. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer has remained largely unchanged. Therefore, there is a need for new treatments and biomarkers to improve outcomes.
One potential drug target for ovarian cancer is the olfactory receptor 4F4 (OR4F4), a G protein-coupled receptor (GPCR) that plays a role in the sense of smell. OR4F4 is a single transmembrane receptor that is expressed in various tissues, including the breast, lung, and brain. OR4F4 has been shown to be involved in various cellular processes, including cell survival, angiogenesis, and drug resistance.
In ovarian cancer, OR4F4 has been shown to be overexpressed or mutated in various subtypes of ovarian cancer. For example, OR4F4 gene expression was significantly increased in ovarian cancer tissues compared to normal tissue. Additionally, OR4F4 has been shown to be a poor predictor of ovarian cancer outcomes, with higher OR4F4 expression being associated with poor prognosis.
Despite these findings, little is known about the clinical applications of OR4F4 as a potential drug target or biomarker for ovarian cancer. In this article, we will discuss the potential clinical applications of OR4F4 as a drug target and biomarker for ovarian cancer.
Potential Drug Target
OR4F4 can be targeted as a drug target due to its unique structure and its involvement in various cellular processes. OR4F4 is a GPCR that is known for its role in the sense of smell. Therefore, small molecules that can modulate OR4F4 function could be developed as potential drugs for ovarian cancer.
One approach to targeting OR4F4 in ovarian cancer is to use small molecules that can inhibit the activity of OR4F4. For example, inhibitors of the androgen receptor (AR), which is a key regulator of OR4F4 function, have been shown to be effective in treating ovarian cancer. In addition, inhibitors of the FAK (focal adhesion kinase), a downstream signaling molecule of OR4F4, may also be effective in targeting OR4F4 in ovarian cancer.
Potential Biomarker
OR4F4 can also be used as a biomarker for ovarian cancer due to its overexpression in various subtypes of ovarian cancer. Ovarian cancer is a heterogeneous disease, with different subtypes that have different clinical outcomes. Therefore, identifying biomarkers that can be specific to different subtypes of ovarian cancer could have implications for personalized medicine.
OR4F4 has been shown to be overexpressed in various subtypes of ovarian cancer, including epithelial ovarian cancer, endometrial ovarian cancer, and ovarian cancer stem cell. Therefore, using OR4F4 as a biomarker could help to identify different subtypes of ovarian cancer and improve treatment outcomes. Additionally, monitoring the expression of OR4F4 could be used as a predictive biomarker for ovarian cancer outcomes.
Conclusion
OR4F4 is a potential drug target and biomarker for ovarian cancer. Its unique structure and involvement in various cellular processes make it an attractive target for small molecules. In addition, OR4F4 has been shown to be overexpressed in various subtypes of ovarian cancer, which could be used as a biomarker for ovarian cancer. Further research is needed to fully understand the clinical applications of OR4F4 as a drug
Protein Name: Olfactory Receptor Family 4 Subfamily F Member 4
Functions: Odorant receptor
The "OR4F4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR4F4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1
